Target intelligence / Profile preview

Influenza A virus hemagglutinin (H1 subtype) (HA)

Target
HA
Molecular classification
Viral surface glycoprotein, Class I fusion protein, Lectin
01

Overview

Influenza A virus hemagglutinin (H1 subtype) is a homotrimeric surface glycoprotein that plays a pivotal role in the viral life cycle by mediating host cell entry. It consists of two subunits, HA1 and HA2, which are generated from a precursor protein (HA0) through proteolytic cleavage by host cell proteases. The HA1 subunit contains the receptor-binding site that recognizes sialic acid residues on the surface of target cells, while the HA2 subunit contains the fusion peptide necessary for merging the viral and endosomal membranes. This fusion process is triggered by the acidic environment of the endosome, which induces a dramatic conformational change in the HA protein.

As the primary antigen on the virus surface, the H1 subtype is the main target for neutralizing antibodies and is a key component of both seasonal and pandemic influenza vaccines. Therapeutic interventions targeting H1 include small molecule inhibitors like umifenovir, which prevents membrane fusion, and various monoclonal antibodies that block either receptor binding or the fusion process. However, the target's high rate of mutation, known as antigenic drift, and its ability to undergo antigenic shift through genetic reassortment present significant challenges for long-term vaccine and drug efficacy. Monitoring HA stability and sequence variations is essential for predicting pandemic potential and selecting appropriate vaccine strains.

Other names
H1HA1 subunitHA2 subunitH1N1 hemagglutininHemagglutinin H1Viral hemagglutinin
02

Mechanism of action

Inhibition of viral entry by blocking the interaction between the hemagglutinin globular head and host cell sialic acid receptors, or by stabilizing the hemagglutinin stem region to prevent the pH-induced conformational change necessary for membrane fusion.

03

Biological functions

Viral entryReceptor bindingMembrane fusionAntigenic determinantHost cell attachment
04

Disease associations

InfectionInfluenzaPandemic influenzaRespiratory disease
05

Safety considerations

Antigenic driftAntigenic shiftDrug resistanceVaccine mismatchViral escape
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Hemagglutination inhibition (HI) titerHA sequence mutationsHA activation pHNeutralizing antibody titer

Beyond the preview

Go deeper on Influenza A virus hemagglutinin (H1 subtype) (HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A virus hemagglutinin (H1 subtype) (HA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call